Items

• Correlation between skin and clinical features in systemic sclerosis By Ljubinka Božić Majstorović , Snježana Popović Pejičić , Irma Ovčina , Verica Ivanović Prodanović , Jelena Mrdja Editor: Siniša Ristić Abstract Introduction. Systemic sclerosis (SS) is a complex autoimmune disease characterized by chronic progressive organic sclerosis. The aim of this paper is to show the correlation of ultrasound (US) parameters with Rodnan skin score (mRSS), as well as the clinical involvement of other org (2024-12)

  LJ. Božić, Correlation between skin and clinical features in systemic sclerosis By Ljubinka Božić Majstorović , Snježana Popović Pejičić , Irma Ovčina , Verica Ivanović Prodanović , Jelena Mrdja Editor: Siniša Ristić Abstract Introduction. Systemic sclerosis (SS) is a complex autoimmune disease characterized by chronic progressive organic sclerosis. The aim of this paper is to show the correlation of ultrasound (US) parameters with Rodnan skin score (mRSS), as well as the clinical involvement of other org, Biomedicinska istraživanja - Časopis Medicinskog fakulteta Foča, Dec, 2024

• Prevalencija intrahospitalnih infekcija na hirurškim klinikama Univerzitetskog kliničkog centra Republike Srpske (2016-04)

  J. Aćimović, S. Kunarac, N. Rodić-Vukmir, L. Božić Majstorović, LJ. Bojanić, Prevalencija intrahospitalnih infekcija na hirurškim klinikama Univerzitetskog kliničkog centra Republike Srpske, STED Journal, Vol. 47, No. 1, pp. 34 - 40, Apr, 2016

• Odgovor na terapiju Rituximabom kod pacijenata sa reumatoidnim artritisom (2010-09)

  LJ. Božić, Odgovor na terapiju Rituximabom kod pacijenata sa reumatoidnim artritisom, ACTA RHEUMATOLOGICA BELGRADENSIA, Sep, 2010

• Prikaz slučaja: '' Vilonodularni sinovitis zgloba kuka'' (2012-09)

  LJ. Božić, Prikaz slučaja: '' Vilonodularni sinovitis zgloba kuka'', ACTA RHEUMATOLOGICA BELGRADENSIA, Sep, 2012

• Prikaz slučaja: Prikaz slučaja pacijentice sa sistemskim eritemskim lupusom I dijabetes melitusom tip 1’’ (2013-03)

  LJ. Božić, Prikaz slučaja: Prikaz slučaja pacijentice sa sistemskim eritemskim lupusom I dijabetes melitusom tip 1’’, ACTA RHEUMATOLOGICA BELGRADENSIA, Mar, 2013

• Prikaz slučaja: '' Sekundarna hipertrofična osteoartropatija'' (2013-06)

  LJ. Božić, Prikaz slučaja: '' Sekundarna hipertrofična osteoartropatija'', INTERNIST, Jun, 2013

• Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks (2016-09)

  LJ. Božić, Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, STED Journal, Sep, 2016

• Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks (2016-09)

  LJ. Božić, Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, STED Journal, Sep, 2016

• Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial (2018-08)

  LJ. Božić, Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial, STED Journal, Aug, 2018

• The importance of renal impairment in systemic sclerosis (2023-06)

  LJ. Božić, The importance of renal impairment in systemic sclerosis, ANNALS OF THE RHEUMATIC DISEASES, Jun, 2023

• The effect of socio-demographic characteristics on the burnout syndrome of nurses in Republic of Srpska during the COVID-19 pandemic (2024-09)

  LJ. Božić, The effect of socio-demographic characteristics on the burnout syndrome of nurses in Republic of Srpska during the COVID-19 pandemic, Scripta Medica, Sep, 2024

• Clinical significance of coagulation factor gene mutations (2024-10)

  LJ. Božić, Clinical significance of coagulation factor gene mutations, Medicinski žurnal, Oct, 2024

• Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis. (2024-12)

  LJ. Božić, Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis., Scripta Medica, Dec, 2024

• Prikaz slučaja: Stilova bolest odraslih (2008-03)

  LJ. Božić, M. Đurica, Ž. Cvijetić, N. Mrkobrada, S. Milovanović, Prikaz slučaja: Stilova bolest odraslih, PONS Medical Journal, No. 13, pp. 38 - 39, Mar, 2008

• Prikaz slučaja Behcet-ove bolesti komplicirane sa duodenalnim ulkusom i hematemezama (2008-06)

  LJ. Božić, M. Đurica, Ž. Cvijetić, N. Mrkobrada, S. Milovanović, Prikaz slučaja Behcet-ove bolesti komplicirane sa duodenalnim ulkusom i hematemezama, PONS Medical Journal, No. 14-15, pp. 34 - 36, Jun, 2008

• Prevalencija intrahospitalnih infekcija na hirurškim klinikama Univerzitetskog kliničkog centra Republike Srpske (2016-04)

  J. Aćimović, S. Kunarac, N. Rodić Vukmir, LJ. Božić, LJ. Bojanić, Prevalencija intrahospitalnih infekcija na hirurškim klinikama Univerzitetskog kliničkog centra Republike Srpske, SCRIPTA MEDICA, Vol. 47, No. 1, pp. 34 - 41, Apr, 2016

• Odgovor na terapiju mikofenolat mofetilom kod pacijentice sa teškim oblikom sistemskog eritemskog lupusa (2016-04)

  LJ. Božić, B. Gašić, D. Jović, M. Vukčević, J. Aćimović, Odgovor na terapiju mikofenolat mofetilom kod pacijentice sa teškim oblikom sistemskog eritemskog lupusa, SCRIPTA MEDICA, Vol. 47, No. 1, pp. 77 - 78, Apr, 2016

• Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks (2016-09)

  C. Hee Suh, A. Berrocal Kasay, E. Chalouhi El-Khouri, P. Miranda, LJ. Božić, S. Jeka, P. Hrycaj, D. Rekalov, P. Wiland, A. Krause, I. Szombati, A. Mihailova, I. Hospodarskyy, M. Piotrowski, S. Ryul Kwon, E. Young Lee, D. Hyun Yoo, W. Park, S. Cheol Shim, S. Joon Lee, T. S. Kwon, Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, STED Journal, pp. 100 - 101, Sep, 2016

• Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks (2016-09)

  W. Park, LJ. Božić, D. Milakovic, A. Berrocal Kasay, E. Chalouhi El-Khouri, F. Irazoque-Palazuelos, F. Fidencio Cons Molina, P. Shesternya, P. Miranda, F. G. Medina-Rodriguez, P. Wiland, S. Jeka, J. Chavez-Corrales, O. Garmish, T. Linde, D. Rekalov, P. Hrycaj, A. Krause, N. Fomina, O. Piura, M. Abello-Banfi, C. Hee Suh, S. Cheol Shim, S. Joon Lee, S. Young Lee, S. Hwan Kim, D. Hyun Yoo, Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, STED Journal, pp. 100 - 101, Sep, 2016

• Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial (2017-07)

  R. Fleischmann, E. Mysler, S. Hall, A. Kivitz, R. Moots, Z. Luo, R. DeMasi, K. Soma, R. Zhang, L. Takiya, S. Tatulych, C. Mojcik, S. Krishnaswami, S. Menon, J. Smolen, LJ. Božić, Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial, LANCET, THE, pp. 457 - 468, Jul, 2017